Correction of a release from 30/09/2019, 14:52 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
October 11, 2019 at 10:30 am EDT
Share
DGAP Total Voting Rights Announcement: Evotec SE
Correction of a release from 30/09/2019, 14:52 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
11.10.2019 / 16:28
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Correction of a publication dated 30.09.2019
1. Details of issuer
Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
2. Type of capital measure
Type of capital measure
Date of status / date of effect
X
Conditional capital increase (Sec. 41 para. 2 WpHG)
30.09.2019
Other capital measure (Sec. 41 para. 1 WpHG)
3. New total number of voting rights:
150529797
11.10.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE 
